T1	intervention 12 18	ginger
T2	condition 38 78	chemotherapy-induced nausea and vomiting
T3	eligibility 82 150	breast cancer patients receiving adriamycin-cyclophosphamide regimen
T4	eligibility 438 563	breast cancer patients receiving AC who experienced moderate to severe nausea or vomiting during the first chemotherapy cycle
T5	control 628 635	placebo
T8	outcome-Measure 955 980	reduction in nausea score
T9	total-participants 982 993	Thirty-four
T10	total-participants 1108 1120	Thirty-three
T6	outcome 1370 1383	nausea scores
T11	outcome 1232 1245	nausea scores
T12	iv-cont-mean 1292 1297	35.36
T14	iv-cont-sd 1299 1304	±4.43
T15	cv-cont-mean 1310 1315	32.17
T16	cv-cont-sd 1317 1322	±3.71
T17	outcome 1057 1069	nausea score
T13	outcome 1513 1544	vomiting incidence and severity
T18	outcome 1546 1567	rescue medication use
T19	outcome 1569 1592	chemotherapy compliance
T20	outcome 1598 1612	adverse events
